Patient tolerability and Estimation of Direct/Productivity costs associated with rapid infusion of daratumumab.

Daratumumab is an anti-CD38 monoclonal antibody FDA approved for use in newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). A phase 2 trial has demonstrated the safety of reducing daratumumab infusion time from 4.5 hours to 1.5 hours. We explored the utilization and cost impacts of a rapid infusion rate for daratumumab in a community-based, quasi-academic setting.